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A 29-year old female presented with a one-week history of vomiting, diarrhoea, abdominal pain, and headache. On admission,
she had acute renal failure requiring dialysis. Tests revealed a hemolytic anemia with thrombocytopenia. An initial diagnosis of
thrombotic thrombocytopenic microangiopathy was made and plasma exchange was instigated. However, renal biopsy did not
show thrombotic microangiopathy but instead revealed acute kidney injury with mild tubulointerstitial nephritis and numerous
oxalate crystals, predominantly in the distal tubules. The patient had been taking large doses (>1100mg daily) of vitamin C for
many months. She also gave a history of sclerotherapy using injections of an ethylene glycol derivative for superﬁcial leg veins. The
patient completed ﬁve sessionsofplasma exchange andwas able todiscontinuedialysis. Sheeventually achieved fullrenal recovery.
She has now discontinued sclerotherapy and vitamin supplementation.
1.Case
A 29-year-old female patient was transferred into the
Renal Unit with acute renal failure requiring emergency
dialysis. She had presented to a peripheral hospital two
days previously, reporting 7 days of frequent vomiting
with possible coﬀee grounds, two episodes of nonbloody
diarrhoea, epigastric pain, thirst, and reduced urine output.
The patient had headache for two days prior to admission.
Past medical history included one normal pregnancy, one
ectopicpregnancy,andamiscarriage,aswellasmenorrhagia.
She had no signiﬁcant family history apart from possible
cases of kidney stones and was taking oral contraceptive
pill. Three months prior to the illness, her urea and crea-
tinine had been routinely checked and were within normal
reference ranges, 5.3mmol/L (14.8mg/dL) and 70µmol/L
(0.79mg/dL), respectively.
On transfer, she was alert, oriented, and hemodynami-
cally stable. Her blood pressure 130/90, pulse 72beats/min
regular, and oxygen saturations were 98% on air, with
a respiratory rate of 16breaths/minute. She was apyrexial.
Urine output was <15mls/hr and she appeared dehydrated
despiteaggressivepretransferintravenousﬂuidtherapyatthe
referring hospital. Clinical examination was unremarkable
apart from localised epigastric tenderness. There were no
purpura, and full neurological examination was normal.
On admission, blood tests revealed a creatinine of
1815µmol/L(21mg/dL),ureaof55mmol/L(154mg/L),and
potassium was 5.1mmol/L and pH 7.35. Hemoglobin was
6.3g/dL, platelets 84 × 10−9/L, and lactate dehydrogenase
(LDH) 2110U/L (220–450). Haptoglobin was <0.30g/L
(0.30–2.00) and absolute reticulocyte count 62 × 10−9 (10–
100). Urine microscopy revealed RBC 52/uL (0–44), and
protein to creatinine ratio was113mg/mmol. A clinical diag-
nosis of hemolytic uremic syndrome/thrombotic thrombo-
cytopenic purpura (HUS-TTP) was made. Dialysis was insti-
gated after biochemistry and urine output failed to respond
to hydration to euvolemia over the subsequent 24 hours.
Onday2,abloodﬁlmwasobtained.Itshowednumerous
red cell fragments (8% of normal cells), acanthocytes,
polychromasia, helmet cells and neutrophilia. Coombs test
was negative. A course of plasma exchange was initiated2 International Journal of Nephrology
using 1.2 plasma volume exchanges [1] against pooled
donor solvent-treated human plasma solution (Octaplas)
and variable proportions of fresh frozen plasma (FFP). An
encouraging response to the initial exchanges was seen with
increase in urine output and rapid reduction in LDH (see
Table 1).
Possible triggers of HUS-TTP were considered. The
patient had been taking the combined oral contraceptive
pill. Serum ßHCG pregnancy test was negative. C3 and
C4 complement levels were normal with negative double
stranded DNA and antiphospholipid antibodies. Other
autoantibodies were negative. Virology and immunology
tests for blood-borne viruses, immunoglobulin levels and
serum electrophoresis, were all negative or within reference
ranges. A stool sample was negative for E. coli 0157.
Laboratory test for ADAMTS13 (AD integrin-like and met-
alloproteinase with thrombospondin type 13 motifs) activity
was 100% (60–133%) analysed by Fluorescence Resonance
Energy Transfer Assays. The normal activity of ADAMTS13
was against the diagnosis of TTP.
The patient reported continued epigastric pain. Serum
amylase and lipase were elevated at 175U/L (<100) and
1047U/L (<300), respectively. Gastroscopy was undertaken
on day 4 to exclude upper gastrointestinal bleed. This
showed mild gastritis only. Samples for Helicobacter pylori
were negative. On the same day, an ultrasound scan of the
abdomen showed no intra-abdominal abnormality and both
kidneys to be normal in size and structure and Doppler
assessed renal blood ﬂow.
Renal biopsy could not be performed until four days
into the treatment course of plasma exchange. No evidence
of thrombotic microangiopathy was present. The biopsy
showed an acute tubulointerstitial pathology characterised
by focal, but marked, acute tubular injury (Figure 1(a)),
with cell sloughing and a mild tubulointerstitial nephritis
(Figure1(b)).Additionally,thepresenceofnumerousoxalate
crystals within both the tubular lumina and the tubular
epithelial cells was conﬁrmed under polarized light (Figures
2(a) and 2(b)). The distal tubules appeared more aﬀected
than the proximal ones. There was no evidence of a
glomerulonephritis or any signiﬁcant vascular pathology.
The various causes of oxalate crystals in the proximal
tubules were thoroughly investigated. Oxalate and glyco-
late levels were not increased in a urine organic acid
proﬁle performed using GC-MS and primary hyperox-
aluria was excluded. Urine oxalate to creatinine ratio was
28µmol/mmol (reference limit 1–38). Plasma oxalate was
demonstrated to be at the upper reference limit at 10µmol/L
(<10). 24-hour urine calcium excretion was not increased at
3.4mmol/24hr (2.5–7.5).
Due to the initial diagnostic uncertainty, a course of
5 sessions of plasma exchange was completed. The patient
required 4 hemodialysis treatments during this course but
was independent of dialysis by its completion. Improvement
in biochemical and hematological parameters is detailed in
Table 1.
On further questioning, the patient eventually admitted
preoccupation with health and appearance. She gave a his-
tory of having undergone three annual courses of sclerother-
apy with Aetoxysclerol single injections for thread veins in
her legs. The treatment was carried out in her home country
o fP o l a n d .T h em o s tr e c e n tc o u r s ew a sf o u rw e e k sp r i o rt o
this admission. She had also been taking Vitamin C in doses
exceeding 1100mg per day for many months (Rutina C and
Vitamin C eﬀervescent), as well as multiple other health and
beautysupplementsforvenousinsuﬃciency(Venorutonand
Diosminum). Our patient was taking them during her acute
illness; however, she discontinued the supplementation of
any tablets after the admission to the hospital.
2. Discussion
This case describes a young female patient initially sus-
pected to have HUS-TTP, but subsequently discovered to
have alternative explanations for the suggestive preliminary
ﬁndings. This highlights the importance of histopathological
conﬁrmations of HUS-TTP. Our patient’s renal biopsy in
fact showed acute tubular injury, and localised severe tubu-
lointerstitial nephritis, consistent with direct toxic tubular
and epithelial damage rather than ischemic/hypovolemic
etiology. The presence of widespread numerous oxalate crys-
tals was unexpected. Oxalate deposition is a well-recognised
feature of acute tubular injury. However, in this case, the
large amount and distribution of the oxalate, including its
presence in many tubular epithelial cells, alerted us to the
possibility of an additional nonacute mechanism. In keeping
with this, we hypothesise that the low-grade tubulointersti-
tial nephritis seen resulted from damaged tubular epithelium
and the consequent release of oxalate crystals into the renal
interstitium.
2.1. Oxalate. The clinical context and laboratory data did
not support endogenous overproduction of oxalic acid as
a possible cause. Neither urinary nor plasma oxalate was
elevated. Plasma oxalate was lower (10µmol/L) than in
primary hyperoxaluria type I and II (>80µmol/L) [2].
It is recognised that the oxalate levels both in plasma and
urine were measured on day 10, after 4 courses of plasma
exchange and 5 courses of hemodialysis. Oxalate removal
might be enhanced during aggressive dialysis that may result
in a prompt recovery of renal function [3]. Oxalate, and its
acid form—oxalic acid, derive primarily from three sources:
the diet, fungi such as Aspergillus and Penicillium and from
humanmetabolism.Foodsespeciallyhighinoxalatesinclude
spinach, beets, chocolate, peanuts, wheat bran, tea, cashews,
pecans, almonds, and berries. Dietary oxalate accounts for
10–20% of the oxalate excreted in the urine [4]. Our
patient was consuming these foods very occasionally, thus
it, was unlikely she was ingesting oxalates in excessive
amounts.
The etiology of oxalate deposition in the kidneys is
probably multifactorial in this patient. Chronic exposure to
both very large doses of vitamin C and the ethylene glycol
derivative (used as the sclerosing agent) may both contribute
to oxalate deposition. Interestingly, secondary oxalosis due
to excessive ingestion of vitamin C was previously described
in patients with acute renal failure who were undergoing
hemodialysis [3].International Journal of Nephrology 3
Table 1: Biochemical and hematological parameters during admission.
Day of in
hospital stay
Creatinine
55–100µmol/L
Hb
11.5–16.5g/dL
LDH (U/L)
(220–450)
Platelets × 10−9/L
(150–450) Blood ﬁlm Plasma exchange (PE)
or hemodialysis (HD)
1 1815 6.3 2205 84 HD (1)
2 1124 9.0 2039 127 PE (1)
2 881 8.8 726 112 HD (2)
3 615 8.7 615 140 PE (2) HD (3)
4 617 7.8
Poikilocytes,
polychromasia,
acanthocytes
PE (3)
7 730 8.8 639 241
Acanthocytes,
polychromasia,
helmet cells, red
cell fragments
( 8 %o fR B C )
HD (4)
7 302 8.8 611 261 PE (4)
8 340 10 573 261 Occasional
schistocyte Biopsy
9 308 9.0 613 230
Approximately
6–8 fragmented
cells per
high-power ﬁeld
seen
PE (5)
10 255 10.2 694 296
3-4 fragments
per high-power
ﬁeld
18 124 10.0 488 261 No fragmented
cells
The resolution of creatinine, hemoglobin, lactate dehydrogenase, thrombocytopenia and fragmented cells on blood ﬁlm, with plasma exchange and
hemodialysis courses over a period of 18 days of in hospital stay. HD: hemodialysis, PE: plasma exchange.
(a) (b)
Figure 1: (a) Renal biopsy on hospital day 8 demonstrating focal marked acute tubular injury with cell sloughing seen in the tubular lumena
(hematoxylin-eosin, X400). (b) Renal biopsy demonstrating tubulointerstitial nephritis; mild oedema and a focal chronic inﬂammatory
inﬁltrate (arrows) present with some evidence of acute tubular injury. Cellular and granular cast formation (at left) (hematoxylin-eosin,
X200).
We hypothesise that oxalate crystals were chronically de-
posited in the renal tubules and that it might have impaired
the patient’s ability to cope with dehydration during an
episode of vomiting and diarrhoea. The vomiting may have
been triggered by gastritis that is supported by gastroscopy
ﬁndings. Vomiting and low-grade diarrhea-associated with
gastritistriggeredhypovolemia-associatedrenaldysfunction.
Vitamin C is a water-soluble vitamin, and dietary excess
is eliminated by the kidney via ﬁltration and active tubular
resorption. The daily requirement is around 75mg for4 International Journal of Nephrology
(a) (b)
Figure 2: (a) Oxalate crystals (arrows) in tubular epithelium and lumena under normal light (Original magniﬁcation X400). (b) Calcium
oxalate crystals () in tubular epithelium and lumena under polarised light (Original magniﬁcation X400).
a woman and 90mg for a man [5] .I t sh a l fl i f ei sa p p r o x -
imately 20 days, and it breaks down to form oxalates in
vivo. A number of studies have investigated vitamin C
metabolism and hyperoxaluric nephropathy. It has been
described in various case reports that vitamin C in doses of
up to 4000mg a day can induce hyperoxaluric nephropathy
and progressive renal failure [6]. Rathi et al. [7]d e s c r i b e d
glomerular and interstitial ﬁbrosis, associated with excessive
vitaminCintake,particularlyinthepresenceofdehydration,
an oxalate-rich diet, or metabolic acidosis Vitamin C-
induced oxalate nephropathy can be a late diagnosis as
individuals may take multivitamin supplements purchased
over the counter on top of dietary sources vitamin C [7].
Oxalosis secondary to Vitamin C administration has been
previously reported in patients with acute renal failure who
are undergoing hemodialysis [8].
Vitamin C administered in excess (≥1g) may also cause
a hemolytic anemia as a consequence of reducing activity of
ascorbic acid on red blood cells. This eﬀect has been noted
in patients with Glucose-6-Phosphate Dehydrogenase (G-6-
PD)deﬁciencyadministeredwithintravenousororaldose of
ascorbic acid [9–11]. We are not aware of G-6-PD status in
our patient.
The role of ethylene glycol derivatives is less clear.
Aetoxysclerol is characterized by its spasmogenic action on
veins. The sclerosant eﬀects of polidocanol are by caus-
ing concentration-dependent diﬀerential cell injury [12].
According to the manufacturer’s information, it is used in
concentrations between 0.3 and 0.6% to treat large varicose
veins or uncomplicated thread veins. It is usually injected
intravenously in concentrations of 0.5–1mL/kg, and the
maximum recommended volume per treatment session is
10mL. By comparison, 0.1mL/kg of pure ethylene glycol
may result in potentially toxic levels. Aetoxysclerol injections
contain polidocanol, an ethylene glycol derivative that is
converted to oxalic acid and is reported to have a low risk
of complications [13–16]. It has not been shown to have a
direct eﬀect on kidneys.
The number, volume, and frequency of sclerosing agent
injections received by the patient were not in excess of the
manufacturer’s recommendations (one injection once a year
f o rt h r e ec o n s e c u t i v ey e a r s ) .T h eh a l fl i f eo fe t h y l e n eg l y c o l
is 3–6 hours, so four weeks after the last injection acute
ethylene glycol toxicity was not suspected. Nevertheless, the
previous exposure to ethylene glycol metabolites may have
predisposed her to oxalate deposition in the kidneys.
Although vitamin C and ethylene glycol are two possible
explanations of oxalate deposits in the kidney, secondary
hyperoxaluria can be also acquired from enteric causes.
After a small bowel bypass, calcium complexes with poorly
absorbed fatty acids and leaves behind excess unbound
oxalate for absorption [6]. This mechanism would explain
the enteric hyperoxaluria in chronic diarrhoea and mal-
absorption. If coexisting, malabsorption, and high-dose
vitamin C could potentiate the hyperoxaluria induced by
each other. However, although our patient had diarrhoea for
2 days prior to the admission to the hospital, the episodic
duration of symptoms would exclude the enteric hyperox-
aluria as a cause of calcium oxalates deposits in the kidney.
The hematological picture is unlikely to have been a
direct consequence of uremia. Brain et al. (1967) reported
that the onset of microangiopathic hemolytic anemia always
preceded the appearance of uremia both in pregnant and
n o tp r e g n a n tw o m e n[ 17]. In our patient, it is diﬃcult to
establish if microangiopathic hemolytic anemia preceded the
uremia. Thus other causes of microangiopathic hemolytic
anemia have been considered. Drug-induced oral contracep-
tive pill-induced hemolysis is one possibility. Our patient has
been on Yasmin (ethinylestradiol and drospirenone) for a
few months, followed by Microgynon (ethinylestradiol and
levonorgestrel) for 3 months prior to the acute presentation.
In the previously described cases, hemolytic uremic syn-
drome was associated with positive steroidal antihormones
antibodies [18–20]. However, renal histopathologic changes
in postpill hemolytic-uremic syndrome were considered
compatible with malignant nephrosclerosis or with throm-
botic microangiopathy [18, 19], rather than acute tubular
injury and oxalate crystals deposits in renal tubules lumina.
Additionally, vitamin C at the dose of 1g taken for 7 days
has been shown to induce unintentionally high plasmaInternational Journal of Nephrology 5
concentrations of ethinylestradiol as the two substances
compete for sulfation in the gut wall, and the vitamin C
interferes with conversion of ethinyl-estradiol (EE2) to its
sulphates [21–23]. As our patient has been taking both
vitamin C and oral contraceptive pill regularly for the three
months prior to the sickness, we may hypothesise that the
acute presentation was an eﬀect of enhanced pill potential
and the drug induction of hemolytic anemia.
The absence of underlying renal disease prior to the
admission to the hospital excludes the hypothesis that
vomiting and diarrhoea were a consequence of chronic
renal disease. The ﬁndings of acute tubular injury are most
likely related to dehydration and renal hypoperfusion in the
setting of vomiting and diarrhoea. It is likely that secondary
oxalosis might have resulted from increased vitamin C
ingestion, oxalates accumulation, and reduced excretion in
renal insuﬃciency. Recovery of renal function was enhanced
by the removal of oxalate with intense dialysis and by the
decrease in oxalate production by limiting the amount of
vitamin C supplementation.
3. Conclusion
The acute tubular injury that this patient developed was
most likely related to dehydration and renal hypoperfusion
caused by vomiting and diarrhoea. The extensive calcium
oxalate deposition found in the kidneys might have been the
result of chronic, excessive vitamin C intake and perhaps
e x p o s u r et oe t h y l e n eg l y c o ld e r i v a t i v e sa sp a r to fc o s m e t i c
sclerotherapy. Although both compounds may contribute to
theoxalateformation,itislikelythatoxalatedepositswerean
incidental ﬁnding that coincided with hemolytic anemia and
acute tubular injury. Renal recovery may have been delayed
by the presence of oxalate deposits.
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